Answers are grounded in this paper and cite their sources.
Membranous nephropathy has historically been associated with a higher risk of malignancy compared to the general population. Following a membranous nephropathy diagnosis, physicians screen patients for underlying cancers at the time of and up to several years following the diagnosis. The discovery of phospholipase A 2 receptor (PLA 2 R) as a major antigen in primary membranous nephropathy may be changing how we think about the association between membranous nephropathy and cancer. PLA 2 R was found to be present in 72% of cases of idiopathic membranous nephropathy with very few PLA 2 R patients having cancer. Following PLA 2 R discovery, thrombospondin type-1 domain-containing 7A (THSD7A) was discovered. This antigen, in contrast to PLA 2 R, may be more strongly associated with cancer. This review will evaluate the associations between these antigens and cancer, as well as propose an algorithm on cancer screening in the era of antibody testing.
No takes yet. Share an insight, caveat, or question.
Khairallah et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: